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Leukotrienes constitute a group of bioactive lipids generated by the 5-lipoxygenase (5-LO) 
pathway. An increasing body of evidence supports an acute role for 5-LO products already 
during the earliest stages of pancreatic, prostate, and colorectal carcinogenesis. Several pieces 
of experimental data form the basis for this hypothesis and suggest a correlation between 
5-LO expression and tumor cell viability. First, several independent studies documented an 
overexpression of 5-LO in primary tumor cells as well as in established cancer cell lines. 
Second, addition of 5-LO products to cultured tumor cells also led to increased cell proliferation 
and activation of anti-apoptotic signaling pathways. 5-LO antisense technology approaches 
demonstrated impaired tumor cell growth due to reduction of 5-LO expression. Lastly, 
pharmacological inhibition of 5-LO potently suppressed tumor cell growth by inducing cell cycle 
arrest and triggering cell death via the intrinsic apoptotic pathway. However, the documented 
strong cytotoxic off-target effects of 5-LO inhibitors, in combination with the relatively high 
concentrations of 5-LO products needed to achieve mitogenic effects in cell culture assays, 
raise concern over the assignment of the cause, and question the relationship between 5-LO 
products and tumorigenesis.
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eosinophils, and basophils) and monocytes/macrophages, which 
constitute the major source of LTs due to high 5-LO expression 
and enzymatic activity. 5-LO expression can also be detected in 
dendritic cells, mast cells, and B-lymphocytes. LTs primarily medi-
ate inflammatory and allergic reactions (Funk, 2001; Tong et al., 
2002;  Ohd et al., 2003; Titos et al., 2003; Yoshimura et al., 2003; 
Zhi et al., 2003; Hayashi et al., 2006) by enhancing chemotaxis of 
migrating neutrophils and triggering vascular permeability and 
edema formation in inflamed tissues. Furthermore, LTs are potent 
bronchoconstrictory agents, crucially involved in asthma patho-
genesis, and enhance plaque formation in foam cells of human 
atherosclerotic tissue. An increasing body of evidence also suggests 
a potential role of 5-LO products in early stage pancreatic, prostate, 
and colorectal carcinogenesis (Qiao et al., 1995; Bortuzzo et al., 
1996; Avis et al., 2001; Ding et al., 2003; Tong et al., 2005).
5-Lipoxygenase catalyzes the first two steps in LT formation. 
Biosynthesis begins with dioxygenation of arachidonic acid (AA) 
released by cytosolic phospholipase A2alpha (cPLA2alpha) from cellular 
phospholipids, which results in two chemically unstable interme-
diates, 5(S)-hydroperoxy-6-trans-8,11,14-cis-eicosatetraenoic acid 
(5-HPETE) and LTA4 (Figure 1). A non-heme coordinated iron atom, 
located in the catalytical site of 5-LO, is involved in both chemical 
reactions. Depending on the cellular enzymes present, LTA4 can be 
either converted to LTB4 by LTA4-hydrolase or conjugated with glu-
tathione by LTC4-synthase to generate LTC4. Further processing of 
LTC4 produces LTD4 and LTE4. 5-HPETE can be reduced by glutath-
ione peroxidases to form the corresponding 5(S)-hydroxy-6-trans-
8,11,14-cis-eicosatetraenoic acid (5-HETE; Radmark et al., 2007). 
IntroductIon
Cancer still ranks the second leading cause of death worldwide 
despite the emergence of a variety of novel therapeutic options 
over the past decade. Malignancy of cells reflects an up-regulation 
of various oncogenic signal cascades that elevate tumor cell pro-
liferation, suppress apoptosis, trigger angiogenesis, and promote 
metastasis. Lipid mediators, such as leukotrienes (LTs) and prostag-
landins constitute a recently discovered class of tumor promoters 
acting by increasing tumor cell viability and triggering metastasis 
inducing events. Pharmacological modulation of these biosyn-
thetic pathways is steadily increasing in importance. The present 
article summarizes several of these experimental findings, which 
implicate an emerging role of 5-lipoxygenase (5-LO)-derived LTs in 
carcinogenesis and critically examines the potential shortcomings 
of previously conducted research. This can provide direction for 
future investigations on 5-LO in tumorigenesis.
5-LIpoxygenase Is a key enzyme In LeukotrIene 
bIosynthesIs
Leukotrienes constitute a group of bioactive lipids that are gener-
ated by the 5-LO pathway. 5-LO expression is typically restricted 
to certain types of leukocytes, such as granulocytes (neutrophils, 
Abbreviations: AA, arachidonic acid; cPLA2alpha, cytosolic phospholipase A2alpha; 
FLAP, 5-lipoxygenase-activating protein; 5-HETE, 5(S)-hydroxy-8,11,14-cis-6-
trans-eicosatetraenoic acid; 5-HPETE, 5(S)-hydroperoxy-6-trans-8,11,14-cis-
eicosatetraenoic acid; 5-LO, 5-lipoxygenase; LT, leukotriene; NDGA, nordihydro-
guaiaretic acid; PPAR, peroxisome proliferator-activated receptors; RTK, receptor 
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Notably, 5-LO is of importance not only for the biosynthesis of 
LTs but also of related bioactive eicosanoids, such as 5-oxo-ETE 
formed by the enzymatic oxidation of 5-HETE (Powell et al., 1992). 
Furthermore, the lipoxins are formed by the cooperative action of 
5- and 15-LO on AA (Serhan et al., 1984) and are involved in pro-
grammed resolution of acute inflammation (Levy et al., 2001).
In resting cells, 5-LO resides in either the nucleus or the cytosol, 
depending on the cell type. Upon activation, 5-LO translocates to 
the nuclear membrane, where the 5-LO activating protein (FLAP) 
is thought to facilitate the transfer of phospholipid-derived AA to 
5-LO and to enhance the efficiency of conversion of 5-HPETE to 
LTA4 thereby triggering 5-LO product formation (Abramovitz et 
al., 1993; Mancini et al., 1993). The LTs produced then exert their 
biological effects by binding to specific G-protein-coupled trans-
membrane receptors at the cell surface denoted BLT1/2 for LTB4 
and CysLT1/2 activated by the cysteinyl LTs (Funk, 2001).
Several pharmacological strategies exist to suppress 5-LO prod-
uct formation. Non-redox and redox type inhibitors, including 
CJ-13,610, Rev-5901, and AA-861 compete with fatty acids for 
binding to the active site cleft(s). Iron-ligand inhibitors such as 
zileuton and BWA4C suppress enzyme activity through chelation 
of the central iron atom and/or by stabilizing the ferrous oxidated 
state. FLAP inhibitors such as MK-886 act indirectly by interfering 
with the availability of AA (Ford-Hutchinson et al., 1994).
studIes that provIde evIdence for a roLe of 5-Lo In 
tumor ceLL proLIferatIon
Increasing evidence in literature implicates 5-LO in the growth of 
several tumor types, including pancreatic, colorectal, prostate, and 
breast cancer. Numerous studies demonstrated overexpression of 
5-LO in tissue samples of primary tumor cells as well as in estab-
lished cancer cell lines (Chen et al., 2006). Addition of 5-LO prod-
ucts to cultured tumor cells led to increased cell proliferation and 
activation of anti-apoptotic signaling pathways (Ding et al., 2003; 
Tong et al., 2005). 5-LO antisense technology approaches impaired 
tumor cell growth by reducing 5-LO expression (Sveinbjornsson 
et al., 2008). Finally, pharmacological inhibition of 5-LO has been 
shown to potently suppress tumor cell growth by inducing cell cycle 
arrest and triggering cell death via the intrinsic apoptotic pathway 
(Ghosh and Myers, 1998; Ding et al., 1999). Based on these findings, 
anti-LT drugs were considered a promising and novel pharmaco-
logical strategy for cancer prevention and therapy.
tumor-assocIated overexpressIon of 5-Lo, Lt receptors and 
other enzymes InvoLved In Lt bIosynthesIs
The first evidence of a potential role for 5-LO in cancer growth 
was based on expression studies reported by Hong et al. (1999), 
who reported that 5-LO and FLAP were universally expressed in 
numerous epithelial cancer cell lines. These findings were in agree-
ment with observations by Hennig et al. (2002), who demonstrated 
increased expression of 5-LO in a set of human pancreatic cancer 
cells and a decreased expression in normal pancreatic ductal cells. 
Subsequently, Gupta et al. (2001) demonstrated 5-LO overexpres-
sion in samples taken from prostate carcinoma patients, where the 
mean level of 5-LO mRNA was sixfold higher in malignant tissues 
compared to healthy tissues. Overexpression was further docu-
mented in malignant pleural mesothelial cells (Romano et al., 2001), 
in bladder carcinomas (Yoshimura et al., 2003), esophageal tumors 
(Zhi et al., 2003), and for breast cancer (Jiang et al., 2003).
In support of this hypothesis, an elevated expression of the LTB4 
receptor was detected in human pancreatic cancer tissue (Hennig 
et al., 2002). Assessing colorectal cancer samples from 84 patients, 
Ohd et al. (2003) were able to show a correlation between expres-
sion of CysLT receptors, 5-LO, an increased viability of the tumor 
cells and declined prognosis for patient survival. Notably, overex-
pression not only applies to 5-LO but also to other 5-LO binding 
enzymes involved in LT biosynthesis. Hong et al. (1999) found 
universal overexpression of FLAP in a series of epithelial cancer 
cell lines. Overexpression of FLAP associated with higher tumor 
aggressiveness and a poor prognosis for survival was demonstrated 
by analyzing breast cancer tissue samples of patients (Jiang et al., 
2006). LTA4 hydrolase overexpression and activity was found to be 
an early event in esophageal and oral adenocarcinogenesis (Chen et 
al., 2004; Sun et al., 2006), whereas a crucial role of LTC4 synthase 
and cPLA2alpha is evident particularly in pathogenesis of leukemia 
(Stenke et al., 1998; Sjolinder et al., 2000; Runarsson et al., 2007). 
Recently, simultaneous overexpression of various enzymes and 
receptors involved in LT biosynthesis and action, including, 5-LO, 
FLAP, LTC4 synthase, LTA4 hydrolase, BLT, and CysLT receptors, was 
detected in the majority of human primary neuroblastoma tumors 
as well as in respective cell lines. Whereas 5-LO is well-recognized 
as pro-carcinogenic, the related enzyme 15-LO-2 is down-regulated 
Figure 1 | Schematic of leukotriene biosynthesis. For detailed description 
see Section 5-Lipoxygenase is a Key Enzyme in Leukotriene Biosynthesis. 
cPLA2alpha, cytosolic phospholipase A2alpha; 5-HETE, 5(S)-hydroxy-8,11,14-cis-6-
trans-eicosatetraenoic acid; 5-HPETE, 5(S)-hydroperoxy-6-trans-8,11,14-cis-
eicosatetraenoic acid; 5-LO, 5-lipoxygenase; FLAP , 5-lipoxygenase-activating 
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which demonstrated potent anti-pancreatic cancer effects by 
inducing tumor cell   apoptosis (Ding et al., 2005) and triggering 
S-phase cell cycle arrest (Tong et al., 2007), further supported 
the hypothesis that 5-LO and its downstream products, play cru-
cial roles in tumorigenesis. Finally, a chemopreventive activity 
of Rev-5901 against colorectal adenocarcinoma xenografts was 
recently demonstrated in an animal tumor model (Melstrom et 
al., 2008). Taken together, the diverse set of 5-LO inhibitors was 
shown to suppress the growth of several types of tumor cells 
by cytotoxic mechanisms, primarily through activation of the 
intrinsic pathway of apoptosis. However, in addition to the pro-
apoptotic activity of the drugs, it should be noted that additional 
anti-proliferative effects were observed, such as a decrease in DNA 
synthesis and induction of cell cycle arrest, which could harbor 
great significance. A summary of the described drug effects can 
be found in Table 1.
mItogenIc effects of 5-Lo products
Several AA metabolites synthesized via the 5-LO pathways have 
been shown to promote tumor cell viability and to exert protective 
effects toward the 5-LO inhibitor induced cytotoxicity. The precise 
molecular mechanisms through which these molecules act on can-
cer cells remain incompletely understood. Direct proliferative and 
anti-apoptotic stimuli as well as an enhanced tumor angiogenesis 
may contribute. 5-HETE and LTB4 increased cell proliferation and 
viability of pancreatic cancer cells by activating the mitogenic and 
anti-apoptotic MAPK and Akt kinase signaling pathways (Ding et 
al., 2003; Tong et al., 2005). A susceptibility toward 5-HETE also 
was described for several other tumor cell types, including breast 
cancer (Avis et al., 2001), and cancer of the lung (Avis et al., 1996). 
The effects of 5-HETE may, at least partially, derive from 5-oxo-
ETE, which is formed by the cellular oxidation of 5-HETE (Powell 
et al., 1992). 5-oxo-ETE acts by binding to the G-protein-coupled 
OXE surface receptors (Grant et al., 2009). Some tumor cell types, 
including colorectal cancer cells, displayed specific mitogenic effects 
in response to LTB4, but not to other 5-LO products (Qiao et al., 
1995; Bortuzzo et al., 1996). A few additional studies report pro-
liferative and anti-apoptotic effects for CysLTs. Accordingly, LTD4 
in malignant tissues, considered to function as a tumor suppres-
sor and to inhibit carcinogenesis (Shappell et al., 1999; Hsi et al., 
2002). The role of 15-LO-1 is still discussed controversially in the 
literature (Pidgeon et al., 2007). Depending on the tumor cell type, 
overexpression of one enzyme of the LT synthesizing machinery in 
tumor cells does not inevitably account for an overexpression of 
the other enzymes. Thus, granulocytes from acute myeloid leuke-
mia patients showed suppressed LTB4 formation accompanied by 
elevated LTC4 hydrolase expression and LTC4 synthesis compared 
to leukocytes from healthy patients (Stenke et al., 1998).
cytotoxIc effects by 5-Lo InhIbItors
Numerous studies have demonstrated cytotoxic and anti- proliferative 
effects of 5-LO inhibitors in cultured tumor cells as an important 
basis for the involvement of 5-LO in tumorigenesis. Tsukada et al. 
were amongst the first to describe the potent anti-proliferative 
effects of the 5-LO inhibitor AA-861 in a human leukemic cell line. 
This was accompanied by a sharp reduction in cellular DNA, RNA, 
and protein synthesis. It was concluded from this result that LTs 
potentially play an essential role in cancer cell viability (Tsukada 
et al., 1986). Similar growth-inhibitory effects were observed with 
the lipoxygenase inhibitor nordihydroguaiaretic acid (NDGA) in 
stomach cancer cells (Shimakura and Boland, 1992).
These data agree well with studies reporting that the 5-LO 
inhibitor AA-861 was capable of abolishing the AA stimulated 
increase of prostate cancer cell growth (Ghosh and Myers, 1997) 
and that inhibition of 5-LO by MK-886 (FLAP inhibitor) triggers 
severe apoptosis in human prostate cancer cells (Ghosh and Myers, 
1998). Subsequent studies described that AA-861 is capable of 
suppressing the growth of esophageal cancer cells in vitro (Hoque 
et al., 2005) and the proliferation of MCF-7 breast cancer cells 
(Hammamieh et al., 2007). AA-861 also has been shown to have 
similar effects in colorectal cancer cells (Ihara et al., 2007). Strong 
cytotoxic effects in various cancer cell lines were also observed 
with the 5-LO inhibitor and LTD4 receptor antagonist Rev-5901 
(Ding et al., 1999; Tong et al., 2002; Titos et al., 2003; Hayashi 
et al., 2006; Melstrom et al., 2008; Sveinbjornsson et al., 2008). 
Recent findings with the LTB4 receptor antagonist, LY293111, 
Table 1 | Cytotoxic and anti-proliferative effects by 5-LO inhibitors in cell culture assays.
inhibitor Concentration (μM) Cell type effects Literature
AA-861 20 Human leukemia cell lines Potent anti-proliferative effects  Tsukada et al. (1986)
AA-861 60 Human prostate cancer cells Inhibition of arachidonic acid 
stimulated cell growth
Ghosh et al. (1997)
MK-886 10 Human prostate cancer cells Triggered cell death via activation of 
the apoptotic pathway
Ghosh et al. (1998)
Rev-5901 15 Human pancreatic cancer cell 
lines
Inhibition of cell proliferation, reversal 
by 5-HETE and 12-HETE
Ding et al. (1999)
LY293111 1 pancreatic cancer cells Inhibition of pancreatic cancer growth, 
induction of tumor cell apoptosis 
Ding et al. (2005)
AA-861 60 Esophageal cancer cells Suppression of cell growth by 
induction of apoptosis
Hoque et al. (2005)
AA-861 30 Human bladder cancer cell lines Strong growth suppression Hayashi et al. (2006)
MK-591, MK-886 20 MCF-7 breast cancer cell line Inhibition of cell proliferation Hammamieh et al. (2007)Frontiers in Pharmacology | Inflammation Pharmacology    December 2010  | Volume 1  |  Article 143  |  4
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increased the proliferation and survival of intestinal epithelial cells 
(Paruchuri et al., 2005) and potentially enhanced tumor growth by 
up-regulating the transcriptional activity of the oncogenic protein 
beta-catenin (Mezhybovska et al., 2006). Romano et al. (2001) were 
able to show that 5(S)-HETE and LTA4 but not LTB4, potently up-
regulated vascular endothelial growth factor (VEGF) transcription 
and expression in a human malignant mesothelioma model, which 
may contribute to the reported pro-angiogenic and anti-apoptotic 
effects of 5-LO products. Recent findings uncovered a novel func-
tion of LTB4 in driving oncogenic ras-induced metastasis by acting 
on BLT-2 receptors (Kim et al., 2009). Furthermore, LTB4-induced 
breast cancer cell survival was linked to BLT-2 mediated generation 
of reactive oxygen species. Collectively, the body of research sup-
ports a model in which 5-LO products modulate proliferative and 
anti-apoptotic events through multiple signaling pathways. Table 2 
provides a summary of the described mitogenic effects.
5-Lo knock-down studIes In cuLtured ceLLs and In 5-Lo 
knock-out anImaLs
Several studies found reduced cell proliferation rates due to down-
regulation of 5-LO expression by antisense approaches. Using 5-LO 
antisense oligonucleotides, Romano et al. (2001) were amongst 
the first to provide direct evidence for 5-LO participation in the 
growth of malignant pleural mesothelial cells. Moreover, reduced 
expression of the 5-oxo-ETE receptor by siRNA approaches signifi-
cantly impaired the viability of prostate cancer cells, suggesting a 
tumorigenic function of the 5-LO product 5-oxo-ETE (Sundaram 
and Ghosh, 2006). Finally, silencing of LT receptors was capable of 
suppressing growth of colorectal cancer cells (Ihara et al., 2007) and 
neuroblastoma cells (Sveinbjornsson et al., 2008). Comparatively 
few studies have investigated the role of 5-LO in mouse models. 
Chen et al. (2009) demonstrated that 5-LO-deficient knock-out 
(KO) mice show significantly impaired induction of chronic mye-
loid leukemia through specific suppression of leukemic stem cell 
proliferation. A summary of experimental findings accounting for 
a role of 5-LO in tumorigenesis can be found in Figure 2.
studIes that questIon the roLe of 5-Lo In 
tumorIgenesIs
cytotoxIc off-target effects of 5-Lo InhIbItors
The increasing number of publications that report a crucial role of 
5-LO, and its products in tumorigenesis have been accompanied by 
additional studies that question the correlation between 5-LO and 
cancer. There is little disagreement that 5-LO inhibitors exert strong 
Table 2 | Mitogenic effects of 5-LO products in cell culture assays.
5-LO product Cell type effect Literature
LTB4 Colorectal cancer cells Increase of cell proliferation Qiao et al. (1995), Bortuzzo et al. (1996)
5-HETE, LTA4 Human malignant pleural 
mesothelial cells
Angiogenic and anti-apoptotic effects, in combination with 
potent up-regulation of vascular endothelial growth factor
Romano et al. (2001)
5-HETE, LTB4 Human pancreatic cancer cells Stimulation of cell viability and proliferation via 
MAPK pathway
Ding et al. (2003), Tong et al. (2005)
LTD4 Intestinal epithelial cells Increase of cell survival and cell proliferation possibly 
mediated via activation of wnt-signaling
Paruchuri et al. (2005), Mezhybovska et 
al. (2006)
c  ytotoxic activities against 5-LO overexpressing tumor types and 
  cultured tumor cells, which represents a significant basis for con-
cluding that 5-LO products directly stimulate tumor cell proliferation. 
However, we recently demonstrated that the common 5-LO inhibitors 
AA-861, Rev-5901, BWA4C, and CJ-13,610 can reduce the viability 
of pancreatic cancer cells, cervix carcinoma cells, and leukemic cells 
independently of suppression of 5-LO product formation (Fischer et 
al., 2010). The hypothesis of 5-LO-independent cytotoxicity and anti-
proliferation was substantiated using several experimental approaches. 
First, the various 5-LO inhibitors were shown to possess highly dif-
ferent abilities to reduce cell viability, to induce cytotoxic effects and 
to suppress the proliferation of cultured 5-LO-positive Capan-2 pan-
creas carcinoma cells. While the commonly used inhibitors AA-861, 
MK-886, and Rev-5901 produced strong cytotoxicity, other, more 
selective and more potent 5-LO inhibitors, including CJ-13,610, 
BWA4C, failed in this respect. Notably, zileuton, the only commercial-
ized 5-LO inhibitor, failed to induce an anti-proliferative or cytotoxic 
response in all types of tumor cells employed. Additionally, the IC50 
values of cytotoxicity for AA-861, MK-886, and Rev-5901 exceeded the 
respective IC50 values for inhibition of 5-LO enzyme activity by more 
than 20-fold (Rev-5901) and upto 5,000-fold (AA-861). Lastly, well-
established 5-LO-negative tumor cell lines exhibited a higher suscep-
tibility toward the 5-LO inhibitors than their morphologically related 
5-LO-p counterparts. These observations are in line with a report by 
Datta et al. in which MK-886 induced severe apoptosis independently 
of FLAP (Datta et al., 1999; Fischer et al., 2010). Sabirsh et al. (2005) 
recently described 5-LO-independent effects of various LT synthesis 
inhibitors on Ca2+ signaling in 5-LO-deficient HeLa carcinoma cells. 
Also the apoptotic effects of licofelone, a dual COX/5-LO inhibitor, 
were found to occur independently of the ability of the drug to affect 
the AA cascade (Tavolari et al., 2008).
Recently, the 5-LO inhibitor zileuton was shown to suppress 
prostaglandin E2 biosynthesis in macrophages with an IC50 value of 
1.94 μM (Rossi et al., 2010), a value which is close to the IC50 of the 
drug for suppression of LT production in cell-based assays (Carter 
et al., 1991). Suppression of the tumor-promoting mediator PGE2 
by zileuton was also observed in human whole blood at clinically 
achievable concentrations and in rats at standard doses. This raises 
concerns over the relationship between the drugs chemopreventive 
effects and suppression of 5-LO.
In contrast to this, some non-tumor cell types showed obvious 
susceptibility toward 5-LO products, such as freshly isolated murine 
neuronal stem cells, which produced considerable basal amounts 
of LTB4 (∼7 ng per 106 cells) and whose growth was suppressed www.frontiersin.org  December 2010  | Volume 1  |  Article 143  |  5
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adenocarcinoma of the pancreas did not reveal any therapeutic 
benefit (Saif et al., 2009). This is a surprising result as a significant 
body of literature has demonstrated a remarkable susceptibility 
of pancreatic cancer cells toward anti-LT drugs in cell culture 
studies (see Cytotoxic Effects by 5-LO Inhibitors) and therefore 
suggests a certain lack of correlation between the effects of 5-LO 
inhibitors in cell culture assays and in patients. Notably, the mean 
Cmax plasma concentrations of the drug achieved in patients after 
a dosage of 600 mg BID were found to be 4.4 μM (Schwartz et al., 
2005) and should lead to almost complete suppression of LTB4 
signal transduction (Marder et al., 1995). Consequently, pleiotropic 
effects of the drug including modulation of PPAR (peroxisome 
proliferator-activated receptor) signal transduction are currently 
discussed (Adrian et al., 2008).
concLusIon and future dIrectIon
A considerable number of studies has provided evidence for a role 
of 5-LO in tumorigenesis. The well-recognized overexpression of 
5-LO in various types of malignant cells, the reduction of tumor cell 
viability by 5-LO gene silencing approaches, as well as experiments 
involving 5-LO KO mice, together constitute a substantial rationale 
for this hypothesis. However, considering that the cytotoxic activity 
of 5-LO inhibitors is substance-specific and may, in many cases, not 
derive from inhibition of 5-LO activity, the traditional hypothesis 
that 5-LO products are the exclusive players in 5-LO-triggered tum-
origenesis may warrant reconsideration. Experiments on the role 
of 5-LO product formation in proliferation of cultured tumor cells 
using high concentrations (>1 μM) of certain 5-LO inhibitors may 
be misleading and the use of these agents as pharmacological tools 
should be critically considered. Also, possible indirect tumorigenic 
effects of 5-LO products (e.g., promotion of angiogenesis) with 
relevance toward the observed situation in vivo but not for cell cul-
ture assays should be taken into account. Notably, non-enzymatic 
functions, including an interaction with cytoskeleton proteins or 
with the adaptor protein Grb-2, involved in receptor tyrosine kinase 
(RTK)-dependent growth factor signaling, have been reported for 
5-LO (Lepley and Fitzpatrick, 1994). Because of the crucial role 
of oncogenic RTK signaling in cancer progression, a disrupted 
growth factor signaling may contribute to the reduction in tumor 
cell viability by 5-LO gene silencing approaches. Thus, experiments 
that assess Grb-2-dependent growth factor signaling after 5-LO 
gene silencing may be instructive. Taken together, a broad body of 
evidence from the literature suggests a crucial, albeit poorly defined, 
role of 5-LO in tumorigenesis of several cancer types. Elucidation 
of the molecular mechanisms underlying these effects may include 
direct proliferative actions of 5-LO products on tumor cells as well 
as indirect and so far neglected effects of 5-LO and thereby draw 
novel connections between pathways that are currently regarded 
as unrelated.
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by AA-861 at concentrations less than 1 μM (Wada et al., 2006). 
Furthermore, zileuton, the only drug devoid of anti-proliferative 
and cytotoxic off-target effects (Fischer et al., 2010), was capable 
of inhibiting the proliferation of RAW 264.7 macrophages below 
1 μM. The macrophages considerably synthesized LTB4 and addi-
tion of physiologically relevant concentrations of LTB4 reversed the 
growth-inhibitory effects of zileuton (Nieves and Moreno, 2006). 
In sum, in many cases, the cytotoxic and chemopreventive effects 
5-LO inhibitors in cell culture assays and in animal tumor models 
may derive from molecular mechanisms other than suppression 
of LT biosynthesis and warrant reassessment.
mItogenIc effects of 5-Lo products
Several studies reported accelerated proliferation of tumor cells in 
the presence of exogenously added 5-LO products and attenuated 
anti-proliferative effects by 5-LO inhibitors (see Mitogenic Effects 
of 5-LO Products, page 3, 2nd paragraph). The extreme concentra-
tions frequently required to observe these effects, however, repre-
sent one caveat to these experiments; the final concentrations of 
5-LO products used often exceeded those present in the medium 
of untreated cells by up to 10,000-fold (Ghosh and Myers, 1998; 
Hoque et al., 2005; Sveinbjornsson et al., 2008). Experiments using 
physiologically relevant concentrations will be one step forward to 
test the mitogenicity and the pleiotropic effects of 5-LO products. 
Experiments are also needed to exclude that high concentrations of 
these 5-LO products induce non-specific anti-apoptotic responses 
that may counteract diverse stimuli or drugs inducing the intrinsic 
pathway of apoptosis.
LackIng evIdence for a cLInIcaL effIcacy of 5-Lo InhIbItors In 
cancer therapy
Few clinical trials have assessed the efficacy of anti-LT drugs in clini-
cal cancer therapy. A randomized double-blind phase II study with 
the LTB4 antagonist LY293111 in patients suffering from advanced 
Figure 2 | experimental evidences accounting for a role of 5-LO in 
tumorigenesis. For detailed description see Section Studies that Provide 
Evidence for a Role of 5-LO in Tumor Cell Proliferation. 5-LO, 5-lipoxygenase; 
LT, leukotriene.Frontiers in Pharmacology | Inflammation Pharmacology    December 2010  | Volume 1  |  Article 143  |  6
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